Detalhe da pesquisa
1.
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).
J Neurol Neurosurg Psychiatry
; 95(5): 392-400, 2024 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37963723
2.
Disease progression in the first 5 years of treatment in multiple sclerosis: Predictive value of early brain and lesion volume changes.
Mult Scler
; 30(1): 44-54, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38018502
3.
Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis.
Mult Scler
; 30(2): 266-271, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38235514
4.
Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod.
Mult Scler
; 30(3): 443-447, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37942812
5.
Neurophysiological MEG markers of cognitive impairment and performance validity in multiple sclerosis.
Mult Scler
; 29(8): 1001-1011, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36964707
6.
Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light.
Mult Scler
; 29(10): 1229-1239, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37530045
7.
Relapse recovery in relapsing-remitting multiple sclerosis: An analysis of the CombiRx dataset.
Mult Scler
; 29(14): 1776-1785, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37830451
8.
The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials.
Mult Scler
; 28(10): 1606-1619, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35876467
9.
Natalizumab concentrations during pregnancy in three patients with multiple sclerosis.
Mult Scler
; 28(2): 323-326, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34931887
10.
Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic.
Mult Scler
; 28(7): 1121-1125, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34240631
11.
Functional brain network organization measured with magnetoencephalography predicts cognitive decline in multiple sclerosis.
Mult Scler
; 27(11): 1727-1737, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33295249
12.
Resting-state MEG measurement of functional activation as a biomarker for cognitive decline in MS.
Mult Scler
; 25(14): 1896-1906, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30465461
13.
4-aminopyridine is not just a symptomatic therapy, it has a neuroprotective effect - Yes.
Mult Scler
; 26(11): 1309-1310, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32628062
14.
Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.
Mult Scler
; 19(5): 593-600, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22992450